LAUSR

Primary headaches represent a global health priority, with an estimated global prevalence of active disorders of 52%, of which migraine accounts for 14%, Tension-Type Headache 26%. On a monthly basis, 4.6% of the global population has headaches for more than 15 days, while on a daily basis 15.8% of all mankind suffer from it [1]. Noteworthy, three out of four people suffering from migraine are women. It is therefore necessary to hypothesize an effective large-scale strategy including risk factor control, such as obesity, cardiovascular diseases, psychiatric diseases, to address this important aspect of clinical medicine. It is important to point out that the majority of migraines can be appropriately managed at a general practitioner’s level, applying pharmacological and non-pharmacological strategies, including neuromodulation. The acknowledgment that this immense group of people with migraine needs appropriate consideration, that stakeholders and policy makers must adequately take in charge this emerging problem, are the yet open challenges that must be faced without further hesitation.